Shares of Nuformix plc (LON:NFX – Get Free Report) were up 5.9% during mid-day trading on Thursday . The stock traded as high as GBX 0.20 and last traded at GBX 0.18. Approximately 53,364,180 shares changed hands during trading, an increase of 39% from the average daily volume of 38,471,695 shares. The stock had previously closed at GBX 0.17.
Nuformix Price Performance
The company’s 50-day moving average price is GBX 0.18 and its 200-day moving average price is GBX 0.23. The company has a market cap of £4.41 million, a P/E ratio of -5.77 and a beta of 1.55.
Nuformix (LON:NFX – Get Free Report) last issued its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
See Also
- Five stocks we like better than Nuformix
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
